



Atty. Docket No.: 22620/2002 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ramakrishan et al.  
Serial No.: 09/904,779  
Filed: July 13, 2001  
Titled: Crystal Structure of the 30S Ribosome

Examiner: Ly Cheyne D.  
Group Art Unit: 1631  
Conf. No.: 1824

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Andrea MacVarish

Name of Person Mailing Paper

*Andrea MacVarish*

Signature of Person Mailing Paper

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF SEQUENCE LISTING AND**  
**AMENDMENT IN RESPONSE TO OFFICE ACTION (QUAYLE) MAILED**  
**SEPTEMBER 30, 2004**

Sir:

This amendment is submitted in response to the Notice that the application is in condition for allowance except for formal matters, specifically the failure of the application to comply with requirements of 37 CFR 1.821 through 1.825 because page 27, line 14 contains an amino acid sequence which requires a sequence ID tag, and said sequence does not have a SEQ ID NO: tag.

Transmitted herewith is a copy of the "Sequence Listing" (sheets 1/2 through 2/2) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the Sequence Listing in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicants Attorney submits the following amendments to comply with 37 C.F.R. §1.825:

**Amendments to the Specification** begin on page 3 of this paper.

**Remarks** begin on page 4 of this paper.

Applicants respectfully request entry of the amendments and remarks.